The firm completed financing actions raising around $1.2 billion in funds that it plans to use to provide financial flexibility and fund corporate objectives.
The UK-based company's revenues are generated exclusively from epigenetic biomarker research and development alliances with commercial and academic partners.
The chip will include coding SNPs identified by Medicinal Genomics using its Kannapedia cannabis genomic database, according to Eurofins.
They collected data on 59 features of more than 100,000 phosphosites and combined those features into a score predictive of a site's functional importance.
According to its developers, the software allows for the quantification several hundred proteins in five-minute DIA analyses of undepleted plasma.
An analysis found a 14 percent prevalence of germline cancer risk mutations and a 57 percent prevalence of variants of unknown significance.
The researchers believe their findings could be used to change how patients' risk for breast cancer, colon cancer, or heart disease is calculated.
The new method, called sci-Plex, combines nuclear hashing and improved single-cell combinatorial indexing RNA-seq to profile the transcriptional response of single cells.
Using pilot data from the GenomeAsia 100K Consortium, researchers searched for long, diverged haplotypes indicative of admixture between modern and archaic humans.
The firm plans to use the proceeds to fund operation and commercial growth as well as development of its Codex and Phenoptics spatial omics platforms.
The database of proteins secreted into blood provides a resource for basic research as well as a potential list of targets for drug and diagnostics development.
With the purchase, Canopy acquires Core's CLIA facility from which it will provide its multi-omic immune profiling services.
The grants were awarded through the organization's Diagnostic Accelerator, a partnership between the charity and various philanthropic partners.
The personalized medicine company hopes to use the new array to inform new consumer and clinical tests, while also making it available to others for research.
The Human Protein Atlas was founded in 2003 to map all the human proteins in cells, tissues, and organs using a variety of omics technologies.
The researchers used the SomaScan platform to measure 5,000 plasma proteins across 17,000 patients and develop protein profiles correlated to 11 health conditions.
Researchers compared single-cell transcriptomic and epigenetic profiles of healthy blood cells and leukemia samples to find a role for RUNX1 in disease.
Biognosys will use its mass spectrometry technology to profile the proteome and phosphoproteome of clinical samples in Indivumed's oncology database.
Geisinger researchers will work with collaborators at the nonprofit FH Foundation to develop new methods for the identification and cascade testing of FH.
The partners are developing a new lab that will focus on research into protein biomarkers with medical, agricultural, and environmental applications.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.